- Home
- MRNA
MRNA
Moderna Inc.
as of 12-24-2025 1:00pm EST
$32.80
+$0.54
+1.67%
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 11.5B | IPO Year: | 2018 |
| Target Price: | $33.25 | AVG Volume (30 days): | 10.6M |
| Analyst Decision: | Hold | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.28 - $48.92 | Next Earning Date: | 02-13-2026 |
| Revenue: | $2,232,000,000 | Revenue Growth: | -56.07% |
| Revenue Growth (this year): | -40.17% | Revenue Growth (next year): | 0.77% |
AI-Powered MRNA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 76.25%
76.25%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Moderna Inc. (MRNA)
AFEYAN NOUBAR
Sell
Director
MRNA Dec 11, 2025
Avg Cost/Share
$29.49
Shares
23,853
Total Value
$703,305.71
Owned After
3,924
SEC Form 4
Hussain Abbas
Sell
Director
MRNA Dec 9, 2025
Avg Cost/Share
$27.60
Shares
504
Total Value
$13,910.40
Owned After
1,515
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| AFEYAN NOUBAR | MRNA | Director | Dec 11, 2025 | Sell | $29.49 | 23,853 | $703,305.71 | 3,924 | |
| Hussain Abbas | MRNA | Director | Dec 9, 2025 | Sell | $27.60 | 504 | $13,910.40 | 1,515 |
Latest Moderna Inc. News
MRNA Breaking Stock News: Dive into MRNA Ticker-Specific Updates for Smart Investing
MT Newswires
Stocks Down Pre-Bell Ahead of Shortened Trading Session
📉
AI Sentiment
Negative
3/10
StockStory
Why Is Moderna (MRNA) Stock Rocketing Higher Today
📈
AI Sentiment
Highly Positive
8/10
Zacks
MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Moderna (MRNA) Valuation Check as CEPI Backs Phase 3 H5 Bird Flu Vaccine with $54.3 Million Funding
📊
AI Sentiment
Positive
7/10
Compare MRNA vs Leading Stocks
See how MRNA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MRNA Moderna Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.